Effectivity of Dysport® in patients with blepharospasm and hemifacial spasm who experienced failure with Botox®

Israel Medical Association Journal

Volumn 10, Issue 7, 2008, Pages 520-522

  Badarny, Samih ^a,b   Susel, Zvil ^a   Honigman, Silvia ^a,b  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Blepharospasm; Botox; Dysport; Hemifacial spasm

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; BLEPHAROSPASM; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HEMIFACIAL SPASM; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; BLEPHAROSPASM; BOTULINUM TOXIN TYPE A; FEMALE; HEMIFACIAL SPASM; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 52049112629     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kessler KR, Skutta M, Beneke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999;246:265-74.
2. Dressler D. Clinical features of secondary failure of botulinum toxin therapy. Eur Neurol 2002;48:26-9.
3. Wittstock M, Benecke R, Bigalke H, Dressler D. Quantitative antibody status in patients with continued sensitivity to long-term botulinum toxin therapy. Neurology 56 (Suppl. 3):A347, 2001.
4. Dressler D. Clinical presentation and management of antibody-induced failure with botulinum toxin therapy. Mov Disord 2004;19(Suppl 8):S92-100.
5. Marion MH, Sheehy S, Sangla S, et al. Dose standardization of botulinum toxin. J Neurol Neurosurg Psychiatry 1995;59:102-3.
6. Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm: mechanism, diagnosis and management. JAMA 1982;248:3160-4.
7. Sampaio C, Ferriera JJ, Simoes F, et al. DYS-BOT: a single blind randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1. Mov Disord 1997;12:1013-18.
8. Nussgens Z, Roggenkamper P. Comparison of two botulinum toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophtalmol 1997;235:197-9.
9. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomized, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-62.
10. Dolimbek BZ, Jankovic J, Attasi MZ. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on primary anti-tetanus antibody response. Immunol Invest 2002;31:247-62.
11. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998;64:13-17.
12. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and non-neutralizing Abs - therapeutic consequences. Exp Neurol 1997;147:96-102.
13. Hatheway CL. Toxigenic clostridia. Clin Microbiol Rev 1990;3:66-98.
14. Smith LA. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 1998;36:1539-48.
15. Houser MK, Sheehan GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry 1998;64:577-80.
16. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulation of botulinum toxin. Mov Disord 2004;19(Suppl 8): S129-36.
17. Kalandakanond S, Coffield JL. Cleavage of intracellular substrates of botulinum toxins A, C and D in mammalian target tissue. J Pharmacol Exp Ther 2001;296:749-55.
18. Jurasinski CV, Leith E, Dang Do AN, Schenground C.L. Correlation of cleavage of SNAP-25 with muscle function in rat model of botulinum toxin type A induced paralysis. Toxicon 2001;39:1309-15.
19. Humeau Y, Doussau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000;82:427-46.
20. Fernandez-Salas E, Ho H, Garay P, Steward LE, Aoki KR. Is the light chain subcellular localization an important factor in botulinum toxin duration of action. Mov Disord 2004;19(Suppl 8):S23-34.